Wegovy 2.4mg — the maintenance dose explained

The biggest misconception: 2.4mg is a destination, not a ceiling

A common belief is that arriving at 2.4mg means you have completed the dose escalation and treatment will now run on autopilot. That is only partially right. For the majority of people in the clinical trial programme, 2.4mg was the intended maintenance dose, the point at which the medicine's effect on appetite suppression and weight reduction is most fully established. Stopping the titration ladder here is not a shortfall. It reflects how the licence was written and how the STEP 1 evidence was generated.

What the misconception misses is that maintenance means sustained clinical engagement, not set-and-forget. Your prescriber will continue to review your progress, assess tolerability and decide whether the dose remains appropriate. How Wegovy's dose schedule is structured matters for understanding why 2.4mg sits where it does: the escalation from 0.25mg upward is designed partly to let your digestive system adapt. Arriving at 2.4mg means that adaptation phase is complete, but ongoing monitoring is not.

The newer 7.2mg dose, approved by the MHRA in January 2026 and updated with a dedicated single-dose pen in April 2026, does represent a higher ceiling for eligible patients. Whether that ceiling is relevant to you is a clinical decision, not a personal one. A prescriber considers your response at 2.4mg, your tolerance and your overall health picture before any discussion of going beyond it.

What 2.4mg actually does in the body, and why the titration matters

Semaglutide at 2.4mg acts on GLP-1 receptors in the brain and gut. It slows the rate at which the stomach empties, raises the hormonal signals that tell the brain food has arrived, and reduces overall appetite. The practical result for most people is eating noticeably less without the usual effort of calorie-counting, though that does not mean the dietary and activity work disappears. The NHS semaglutide information page describes these effects in plain terms and is worth reading alongside this page.

The reason titration runs from 0.25mg rather than starting at 2.4mg is straightforward: nausea and GI discomfort are far more common at higher doses when the body has not had time to adjust. Each step (0.25mg, 0.5mg, 1.0mg, 1.7mg, then 2.4mg) is typically held for around four weeks. That means reaching 2.4mg generally takes about four months from first injection.

One practical habit worth building at this stage: before each new pen, check the liquid through the pen window. It should be clear and colourless. Anything cloudy, discoloured or containing visible particles means the pen should not be used. It takes under a minute and is the kind of check that catches a storage problem early. If you have questions about the 2.4mg pen itself (how it looks, how the mechanism works) that page covers the detail.

Side effects at 2.4mg: what the evidence shows at maintenance dose

Gastrointestinal effects are the most reported side effects across the semaglutide programme. Nausea tops the list, followed by loose stools, constipation, burping and indigestion. At 2.4mg specifically, these effects are often more prominent in the first few weeks after reaching the dose, then settle for most people. The STEP 1 trial showed they were typically mild to moderate and transient, though some participants reduced their dose because of them.

Pancreatitis is a less common but more serious consideration. In January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as an infrequent but serious risk across GLP-1 medicines. Severe, persistent stomach pain that radiates toward the back (with or without vomiting) needs urgent medical attention, not a wait-and-see approach. Reporting any suspected side effects through the MHRA Yellow Card scheme helps regulators track real-world safety signals.

Fatigue and headache are also reported, often early in treatment. Dehydration from nausea or vomiting can compound both; keeping fluid intake consistent is one of the more practical things a prescriber will raise at this stage. If you are transitioning from 1.7mg and want a direct comparison of how patients experience that step, the 1.7mg versus 2.4mg page covers the differences in tolerability and effect.

Who reaches 2.4mg through a private prescription, and what that route looks like

Under the UK licence, Wegovy is approved for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition, hypertension, type 2 diabetes, raised cholesterol, obstructive sleep apnoea or similar. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. The starting point is always clinical assessment; BMI alone does not determine suitability.

On the NHS, access to Wegovy at any dose, including 2.4mg, remains limited to specialist weight management services under NICE technology appraisal TA875, and waiting lists are often long. Private prescribing through a regulated online pharmacy is the alternative route for people who cannot access NHS provision or prefer not to wait. If you want to understand how Wegovy works as a treatment more broadly before thinking about access, that overview covers the full picture.

A note on cost: private treatment at any dose level involves a transparent price that should include the consultation, prescription, and delivery, not just the pen itself. What gets left off a headline price is worth checking before you commit. For patients specifically moving up to the step from 1.7mg to 2.4mg, that page explains what to expect from the transition and how it is managed through a private prescription. For a fuller look at how Wegovy is priced through private providers, the weight-loss treatment overview gives useful context without glossing over the numbers.

At nume, every prescription is reviewed by a GPhC-registered Independent Prescriber who reads your consultation the same day. If you are clinically suitable, treatment is dispatched the same working day and arrives via tracked DPD delivery the following working day, in plain packaging. For patients confirmed at maintenance, the 2.4mg Wegovy page covers everything relevant to that specific dose before you begin. Check your eligibility to start that conversation with our prescribers.